Scalp psoriasis

Wozel, Gottfried; Klein, E.; Mrowietz, Ulrich; Reich, Kristian; Sebastian, Michael; Streit, Volker

doi:10.1111/j.1610-0387.2010.07412.x

Cited by 26 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that involvement of the scalp inflicts psychosocial problems due to the visibility of the lesions, and at the same time scalp psoriasis is difficult to treat. 12 The present results showed that, by the time of the complete assessment, 90% or more of skin lesions in the head region disappeared in approximately 50% of patients, with complete disappearance in approximately 41%. High PASI 75 and PASI 90 response may be achieved via the effect of infliximab irrespective of the body area.…”

Section: Discussionmentioning

confidence: 67%

Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

Torii¹,

Sato²,

Yoshinari³

et al. 2011

The Journal of Dermatology

View full text Add to dashboard Cite

European S3 Guidelines on the systemic treatment of psoriasis in 2009 propose 75% or more improvement in the Psoriasis Area and Severity Index from baseline (PASI 75) and a Dermatology Life Quality Index (DLQI) of 0 or 1 as treatment goals. However, the relationship of these two parameters is yet to be clarified. Herein, we analyzed the data pooled from two Japanese phase III clinical trials on psoriasis with infliximab to clarify the PASI response necessary to achieve a DLQI of 0 or 1. Of the 90 patients, the mean percent improvement in PASI at week 50 or 66 was 74.5%, and the PASI 75 and PASI 90 response rates were 66.7% and 46.7%, respectively; no difference in the improvement was noted among the body areas. Significant improvements in nail psoriasis were also observed. A negative correlation was shown between the improvement in PASI and DLQI. Patients who achieved a PASI 90 response had a significantly higher percentage of achieving a DLQI of 0 or 1 than the patients who achieved a PASI 75 but not a PASI 90 response. The median serum trough level of infliximab was maintained at 2 lg ⁄ mL or more in the PASI 90 responders, whereas it was less than 1 lg ⁄ mL at week 30 and on in the others. The present results demonstrate that a PASI 90 response is necessary to achieve a DLQI of 0 or 1. Infliximab is considered a useful drug in meeting the treatment goal of achieving a DLQI of 0 or 1 through the attainment of a PASI 90 response.

show abstract

Section: Discussionmentioning

confidence: 67%

Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

Torii¹,

Sato²,

Yoshinari³

et al. 2011

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Safety data were prospectively collected based on side‐effects reported by the patients and observations of the physician at each visit. Scalp psoriasis severity was expressed by the Psoriasis Scalp Severity Index (PSSI; range 0–72) . The PSSI is calculated by a 5‐point scale (0 = no symptoms to 4 = very severe) for each individual symptom (redness, scaling and infiltrate).…”

Section: Methodsmentioning

confidence: 99%

“…The PSSI is calculated by a 5‐point scale (0 = no symptoms to 4 = very severe) for each individual symptom (redness, scaling and infiltrate). These three scores are added and multiplied with a score for the percentage of the scalp involved (0 = 0% to 6 = 90%–100%) . Clinical severity of psoriasis was assessed by a clinician using Psoriasis Area and Severity Index (PASI; range 0–72) …”

Section: Methodsmentioning

confidence: 99%

Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice

Oostveen

Jong

Donders

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Sir : Malassezia ( Pityrosporum ) is a yeast fungus that has been known to cause tinea versicolor skin, scalp psoriasis, 1 otomycosis, 2 and catheter‐related fungaemia 3 . The existing literature does not contain any evidence on Malassezia infestation of the deep subcutaneous or joint tissues.…”

mentioning

confidence: 99%

“…Malassezia is a soil‐borne yeast contributing to the normal flora of the skin, and is known to cause opportunistic parasitization of the keratinized and waxy surfaces of the epidermis 1,2 . The incidence of Malassezia fungaemia in catheterized immunocompromised patients in some previous studies 3 showed that yeast from the epithelial surface was prone to blood‐borne spread.…”

mentioning

confidence: 99%